Skip to content

Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Collagen Scaffold in the Treatment of Thin Endometrium

Clinical Study of Stem Cells in the Treatment of Thin Endometrium

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03724617
Enrollment
18
Registered
2018-10-30
Start date
2018-10-29
Completion date
2020-12-31
Last updated
2021-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine Adhesion, Thin Endometrium

Keywords

thin endometrium, Intrauterine Adhesion, stem cell, Collagen scaffold

Brief summary

This is a non-blind self-control trial. We mainly compare the changes of endometrial thickness,changes in menstrual flow, and improvement in pregnancy before and after stem cell treatment in patients with thin endometrium.

Detailed description

According to the medical history and the results of the examination, the selected cases were screened and the informed consent was signed. After hysteroscopy, the collagen/umbilical cord mesenchymal stem cell was spread on a foley catheter, and placed in the uterine cavity, and 5 ml of saline was filled into the balloon. B-ultrasound confirmed that the stent was attached to the uterine wall. The balloon was removed in situ after 1 week. We mainly compare the endometrial thickness before and 6 months after surgery.

Interventions

DRUGumbilical cord mesenchymal stem cells combined with collagen scaffold

3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.

Sponsors

Sir Run Run Shaw Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. According to the GCP regulations, obtain the informed consent of the subject, volunteer for the test, and have signed the informed consent form. 2. Women aged 20-40 years with fertility requirements 3. Infertility patients who are treated in this hospital 4. After more than 2 times of hysteroscopic adhesion separation surgery, the uterine cavity morphology has basically returned to normal. The patient has a normal menstrual cycle or an estrogenic dose of 6 mg per day, and the highest thickness of the endometrium is 5.5 mm in 6 cycles by ultrasound. 5. or receive adjuvant reproductive treatment, the endometrial thickness is less than 5.5mm for unknown reasons, the treatment of estrogen, colony stimulating factor, aspirin, sildenafil and other drugs up to 8mg / day is invalid. 6. HBVAg negative, HCV negative, HIV negative, syphilis negative 7. Normal bone marrow morphology, normal blood routine 8. Previously failed to receive relevant stem cell therapy

Exclusion criteria

1. Those who cannot accept the treatment observation process required by the test 2. There are contraindications for hysteroscopic surgery; 3. congenital uterine malformation; severe adenomyosis; uterine fibroids that may affect embryo implantation; the investigators judged that there are other uterine factors that are not suitable for embryo implantation 4. Patients with chromosomal abnormalities 5. contraindications to estrogen therapy; systemic diseases such as thrombosis, cardiopulmonary disease, hematopoietic diseases, malignant tumors, etc. 6. Patients without fertility requirements

Design outcomes

Primary

MeasureTime frameDescription
the change of endometrial thicknessChange from Baseline endometrial thickness at 6 monthsB-ultrasound measures and compares the endometrial thickness of the luteal phase before and after administration.

Secondary

MeasureTime frameDescription
pregnancy ratepregnancy rate at 1 yearpregnancy rate = (pregnancy / observations) × 100%
live birth ratelive birth rate at 1 yearlive birth rate = (live births / observations) × 100%
abortion rateabortion rate at 1 yearabortion rate = (number of abortions / observations) × 100%

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026